Search or
𝛼SK
𝛼SKbullish
BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision
Tina has highlighted this Insight as a Top Pick
463 Views09 Aug 2025 00:30
BeiGene reported strong 2Q25 revenues of $1.3B, driven by Brukinsa sales in US and Europe. U.S. Brukinsa sales outpaced competitor for three consecutive quarters. Revenue guidance for 2025 increased.
What is covered in the Full Insight:
- Introduction to BeiGene's Q2 2025 Performance
- Brukinsa's Market Leadership in U.S.
- Updated 2025 Financial Guidance
- Clinical Pipeline Developments
- Outlook and Valuation Analysis
Boomeranged on Mon, 1 Sep 2025 06:36
Beigene announced positive topline results from Phase 1/2 study of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). The result underscores sonrotoclax's potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »- BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision
- BeiGene (6160.HK/ONC US) 25Q2 - The High Growth of BRUKINSA May Not Bring High Valuation
- China Healthcare Weekly (Aug.10)-Trump Plans Drug Tariff, Biosimilar VBP, BeiGene's Headwind in 25Q2
- Continue Adding Exposure to China; Short-Term Supports to for This ACWI-US Pullback
- Quiddity Leaderboard Hang Seng Index Jun25: Beigene Is Our Top Pick
Trending Collections
More »Trending Insights
More »- [Japan ECM] Lifedrink (2585) - Fast-Growing Beverage Seller Meets P.E. Firm Selldown
- HKBN (1310 HK): On the Cusp of Being Declared Unconditional
- Shandong Gold Mining Placement - H-Share Running Ahead of A-Shares
- Ohayo Japan | Defence Shares Lead EU Gains; US Closed
- Pre-IPO Aux Electric Co (PHIP Updates) - Concerns About Business Model and Valuation Outlook
Top Unpaywalled Insights
More »- Curator's Cut: Arbs Go A-H, Copper Plays & China's Property Pulse
- Tencent's Uzbekistan Bet: The Beginning Of "Digital Silk Road"?
- [IO Technicals 2025/35] Iron Ore Bulls Charge on Tight China Supply
- A Monetary View on US Inflation
- At the US-Korea Summit, Samsung’s Next Move Could Reshape the US Chipboard
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision09 Aug 2025
- BeiGene (6160 HK): Brukinsa Outpaces Competitor in 4Q US Sales; Solid Guidance for 202501 Mar 2025
x